Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4

AIDS Research and Human Retroviruses

Volumn 12, Issue 11, 1996, Pages 1015-1021

  Klasse, P J ^a,b   Sattentau, Quentin J ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; SYNCYTIUM; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS MUTATION;

EID: 0029764165     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.1015     Document Type: Article

References (28)

1. Weiss RA: Cellular receptors and viral glycoproteins involved in retroviral entry. In: The Retroviridae (Levy J, ed.). Plenum Press, New York, 1993, pp. 1-108.
2. Klasse PJ, Moore JP, and Jameson BA: The interplay of the HIV-I envelope complex, gp120 and gp41, with CD4. In: HIV Molecular Organization, Pathogenicity and Treatment (Morrow WJW and Haigwood NL, eds.). Elsevier, Amsterdam, 1993, pp. 241-266.
3. Healy D, Dianda L, Moore JP, McDougal JS, Moore MJ, Estess P, Buck D, Kwong PD, Beverly PCL, and Sattentau QJ: Novel anti-CD4 monclonal antibodies separate HIV infection and fusion of CD4+ cells from virus binding. J Exp Med 1990;172: 1233-1242.
4. Moore JP, Sattentau QJ, Klasse PJ, and Burkly L: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992;66:4784-4793.
5. Klasse PJ and McKeating JA: Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: A phenotypic characterization. AIDS Res Hum Retroviruses 1993;9:595-604.
6. Burkly LA, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, and Chisholm P: Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. J Immunol 1992;149:1779-1787.
7. Rocancourt D, Bonnerot C, Jouin H, Emerman M, and Nicolas J-F: Activation of a β-galactosidase recombinant provirus: Application to titration of the human immunodeficiency virus (HIV) and HIV-infected cells. J Virol 1990;64:2660-2668.
8. Clapham PR, Blanc D, and Weiss RA: Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 1991;181:703-715.
9. Wain-Hobson S, Vartanian J-P, Henry M, Chenciner N, Cheynier R, Delassus S, Pedroza-Marins L, Sala M, Nugeyre MT, Ouetard D, Klatzmann D, Gluckman JC, Rozenbaum W, Barre-Sinoussi F, and Montagnier L: LAV revisited: Origins of the early HIV-1 isolates from Institut Pasteur. Science 1991;252:961-965.
10. Klasse PJ, McKeating JA, Schutten M, Reitz MS Jr, and Robert-Guroff M: An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 HXB2-Env:Ala 582(→Thr) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology 1993;196:332-337.
11. Gorny MK, Gianakakos V, Sharpe S, and Zolla-Pazner S: Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci USA 1989;86:1624-1628.
12. Cordell J, Moore JP, Dean CJ, Klasse PJ, Weiss RA, and McKeating JA: Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology 1991;185:72-79.
13. Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA, Johnson JS, Cossum P, Chamow SM, Wurm FM, Gregory T, Groopman JE, and Capon DJ: Biological properties of a CD4 immunoadhesin. Nature (London) 1990;344:667-670.
14. Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos D, Liu T, Tizard R, Walker B, Hirsh MS, Schooley RT, and Flavell RA: HIV infection is blocked in vitro by recombinant soluble CD4. Nature (London) 1988;331:76-78.
15. Moore JP: Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS 1990;4:297-305.
16. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4. J Exp Med 1991;174:407-415.
17. Sattentau QJ, Moore JP, Vigneaux F, Traincard F, and Poignard P: Conformational changes induced in the envelope glycoproteins of human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993;67:7383-7393.
18. Kirsh R, Hart TK, Ellens H, Miller J, Petteway SA Jr, Lambert DM, Leary J, and Bugelski PJ: Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1. AIDS Res Hum Retroviruses 1990;10:1209-1212.
19. Moore JP, McKeating JA, Weiss RA, and Sattentau QJ: Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990;250:1139-1142.
20. Sattentau QJ, Zolla-Pazner S, and Poignard P: Exposed and masked epitopes on functional, oligomeric gp41 molecules. Virology 1995; 206:713-717.
21. Myers G, Korber B, Berzofsky JA, Smith RF, and Pavlakis GN, eds.: Human Retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, New Mexico, 1993.
22. Klasse PJ, Boyd MT, Weiss RA, and Schulz TF: Mutations in the vpu, env and nef genes of a syncytium-inducing variant of HIV-1-JR-CSF that infects a range of T-cell lines. AIDS Res Hum Retroviruses 1996;12:347-350.
23. Moore JP, Burkly LC, Connor RI, Cao Y, Tizard R, Ho DD, and Fisher RA: Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res Hum Retrovirases 1993;9:529;-539.
24. Moore JP, McKeating JA, Huang Y, Ashkenazi A, and Ho DD: Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992;66:235-243.
25. Sullivan N, Sun Y, Li J, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-4422.
26. Kabat D, Kozak S, Wehrly K, and Chesebro B: Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol 1994;68:2570-2577.
27. Klasse PJ and Moore JP: Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of the human immunodeficiency virus type 1. J Virol 1996;70:3668-3677.
28. Poignard P, Fouts T, Naniche D, Moore JP, and Sattentau QJ: Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J Exp Med 1996;183:473-484.